Effect of Pioglitazone on Cardiovascular Outcome on Higashi-Saitama Trial in Patients With Type 2 Diabetes

Dokkyo Medical University

Status: Completed

Conditions: Diabetic Nephropathy; Hypertension; Dyslipidemia; Type 2 Diabetes

Treatments: Drug: pioglitazone

Study type: Observational

Funder types: Other

Identifiers

NCT00419484

0309

Details and patient eligibility

About

We want to investigate the effects of pioglitazone on cardiovascular events in Japanese patients with type 2 diabetes.

Full description

Primary composite endpoints:

Cardiovascular death Non-fatal myocardial infarction and angina Non-fatal stroke Renal failure (hemodialysis/doubling of serum creatinine)

Secondary endpoints:

urinary albumin excretion diabetic retinopathy hyperlipidemia hypertension gout

Sex: All

Ages: 20 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• type 2 diabetes HbA1c: more than 7% and less than 9%

Exclusion criteria

• insulin treatment